Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Dimethyl fumarate (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CONNECT
- Sponsors Biogen
Most Recent Events
- 29 Sep 2024 This trial has been completed in Belgium, as per European Clinical Trials Database record.
- 11 Sep 2024 This trial has been completed in Hungary.
- 17 Nov 2021 This trial has been completed in Germany, according to European Clinical Trials Database record.